Media coverage about Lipocine (NASDAQ:LPCN) has been trending somewhat positive this week, according to Accern Sentiment. The research firm identifies negative and positive media coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Lipocine earned a news sentiment score of 0.13 on Accern’s scale. Accern also assigned headlines about the specialty pharmaceutical company an impact score of 45.6436319944091 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
Here are some of the news headlines that may have impacted Accern’s rankings:
- HC Wainwright Analysts Give Lipocine (LPCN) a $3.00 Price Target (americanbankingnews.com)
- Lipocine to Present at the Oppenheimer 28th Annual Healthcare Conference – PharmiWeb.com (press release) (pharmiweb.com)
- Lipocine (LPCN) Rating Reiterated by Canaccord Genuity (americanbankingnews.com)
Shares of Lipocine (LPCN) traded up $0.01 on Tuesday, hitting $1.49. 182,479 shares of the stock traded hands, compared to its average volume of 840,549. The firm has a market cap of $32.32, a PE ratio of -1.43 and a beta of 0.35. Lipocine has a 12 month low of $1.15 and a 12 month high of $5.33.
LPCN has been the topic of several research analyst reports. HC Wainwright reissued a “buy” rating and set a $10.00 target price on shares of Lipocine in a research note on Friday, December 8th. Canaccord Genuity reaffirmed a “hold” rating and issued a $2.00 price objective (down previously from $11.00) on shares of Lipocine in a research note on Tuesday, January 9th. Finally, Ladenburg Thalmann Financial Services reaffirmed a “buy” rating and issued a $11.00 price objective on shares of Lipocine in a research note on Thursday, January 11th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the company. Lipocine presently has a consensus rating of “Hold” and a consensus target price of $13.50.
ILLEGAL ACTIVITY WARNING: “Lipocine (LPCN) Earning Somewhat Positive News Coverage, Analysis Finds” was originally reported by Community Financial News and is the sole property of of Community Financial News. If you are accessing this article on another site, it was illegally stolen and republished in violation of United States and international copyright & trademark law. The legal version of this article can be read at https://www.com-unik.info/2018/03/20/lipocine-lpcn-earning-somewhat-positive-news-coverage-analysis-finds.html.
Lipocine Inc is a specialty pharmaceutical company. The Company is focused on applying its oral drug delivery technology for the development of pharmaceutical products in the area of men’s and women’s health. Its primary development programs are based on oral delivery solutions for bioavailable drugs.
Receive News & Ratings for Lipocine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lipocine and related companies with MarketBeat.com's FREE daily email newsletter.